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Resumo 
As células cancerígenas são o resultado de um processo gradual e complexo chamado oncogénese. 
Durante este processo, as células normais transformam-se progressivamente em células cancerígenas 
através da acumulação de diversas alterações genéticas, que eventualmente culminam numa ou mais 
características definidas como ‘’hallmarks of cancer’’. Estas características foram definidas como 
propriedades essenciais ao desenvolvimento cancerígeno por Hanahan and Weinberg e correspondem 
a: sustentar sinalização proliferativa, escapar aos supressores tumorais, resistir à morte celular, 
possibilitar imortalidade replicativa, induzir angiogénese e ativar processos de invasão e 
metastastização. Este conjunto de características foi mais tarde alargado, considerando igualmente a 
importância da instabilidade genómica e da inflamação, bem como da reprogramação do metabolismo 
e do escape à vigilância imunitária no desenvolvimento dos processos tumorais. 
O carcinoma da tiroide é a neoplasia maligna mais frequente do sistema endócrino e a sua incidência 
tem vindo a aumentar ao longo dos últimos anos. De acordo com as suas características histológicas e 
morfológicas, o carcinoma da tiroide pode ser subdividido em quatro subtipos principais: carcinoma 
medular da tiroide (MTC, medullary thyroid cancer), carcinoma papilar da tiroide (PTC, papillary 
thyroid cancer), carcinoma folicular da tiroide (FTC, follicular thyroid cancer) e carcinoma anaplástico 
da tiroide (ATC, anaplastic thyroid cancer). Os subtipos PTC, FTC e ATC desenvolvem-se a partir das 
células epiteliais foliculares da glândula da tiroide, enquanto que o subtipo MTC deriva das células 
parafoliculares. Para além disso, dentro dos grupos que se desenvolvem a partir das células foliculares, 
os subtipos papilar e folicular são considerados carcinomas da tiroide bem diferenciados (WDTC, well-
differentiated thyroid cancer), enquanto que o subtipo anaplástico corresponde a um tipo de carcinoma 
da tiroide indiferenciado.  
O carcinoma papilar da tiroide é o subtipo mais frequentemente diagnosticado, correspondendo a 
cerca de 80% dos casos dos carcinomas da tiroide. Normalmente, os doentes com estas formas 
apresentam um prognóstico favorável após remoção total ou parcial da glândula da tiroide e, quando se 
justifique, terapia com iodo radioativo. No entanto, existe um subconjunto de doentes que apresentam 
formas agressivas da doença, frequentemente associadas a resistência à radioterapia com iodo e para os 
quais não existem alternativas terapêuticas eficazes, sendo por isto essencial o desenvolvimento de 
novas estratégicas terapêuticas. As alterações genéticas mais frequentemente associadas ao carcinoma 
papilar da tiroide incluem mutações pontuais no gene BRAF ou rearranjos RET/PTC. Uma vez que estas 
alterações promovem a ativação constitutiva da via de sinalização MAPK (mitogen activated protein 
kinase), esta por sua vez é considerada essencial ao desenvolvimento do cancro da tiroide. Por outro 
lado, mutações pontuais no gene RAS também podem ser encontradas em doentes com o subtipo papilar. 
À semelhança dos rearranjos RET/PTC, as mutações em RAS têm a capacidade de ativar tanto a via de 
sinalização das MAPK, como a via PI3K/Akt/mTOR. Neste sentido, também a via de sinalização 
PI3K/Akt/mTOR tem vindo a ser considerada um elemento importante durante o desenvolvimento e 
progressão do cancro da tiroide. Sendo o carcinoma papilar da tiroide, um cancro que envolve 
frequentemente a ativação constitutiva da via MAPK, uma terapêutica dirigida à inibição da mesma 
poderia ser uma opção. No entanto, efeitos secundários indesejados associados ao uso de inibidores 
desta via, têm vindo a ser reportados em doentes com diferentes formas de carcinoma da tiroide, bem 
como o escape à terapêutica após longos períodos de tratamento. Desta forma, a compreensão dos 
mecanismos moleculares subjacentes à oncogénese do subtipo papilar e, em particular, da interação 
entre diferentes vias de sinalização implicadas, poderá ser uma mais valia no desenvolvimento de novas 
terapias dirigidas aos doentes com as variantes agressivas. 
A via de sinalização PI3K/Akt/mTOR é umas das vias mais estudadas no contexto da tumorigénese, 
devido ao seu papel determinante na proliferação e sobrevivência celular. No carcinoma da tiroide, 
mutações que afetam esta via costumam ser mais comuns nos tipos foliculares e anaplásticos. No 
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entanto, pensa-se que esta via tem um papel importante na progressão de PTC para formas mais 
agressivas. Para além disso, como algumas das mutações associadas ao carcinoma papilar da tiroide 
também têm a capacidade de promover uma ativação da via de sinalização PI3K/Akt/mTOR, também 
esta via acaba por representar um alvo apelativo ao desenvolvimento de novas terapêuticas dirigidas, 
visando as formas agressivas.  
O NF-κB é um fator de transcrição, cuja desregulação pode facilmente promover condições 
favoráveis ao desenvolvimento cancerígeno, devido ao controlo que exerce sob diversas funções 
biológicas, tais como na inflamação ou em mecanismos associados à apoptose, crescimento e 
proliferação celular. No contexto do cancro da tiroide, este fator de transcrição tem sido descrito como 
um elemento envolvido na resistência à terapêutica, o que leva a suspeitar da presença de algum tipo de 
interação entre a via de sinalização do NF-κB e as vias de sinalização mais relevantes ao processo 
oncogénico da tiroide. De facto, uma relação entre a via de sinalização MAPK e a via canónica do NF-
κB, foi já descrita por vários autores em diferentes modelos de carcinoma da tiroide, incluindo o subtipo 
papilar. No entanto, uma interação entre as vias NF-κB e PI3K/Akt/mTOR não se encontra ainda 
descrita no contexto das neoplasias da tiroide. O principal objetivo deste trabalho foi investigar esta 
interação em modelos celulares de carcinoma papilar da tiroide. Neste sentido, foram estabelecidas três 
abordagens experimentais que consistiam na avaliação da atividade do NF-κB: i) na presença de 
inibidores químicos da via PI3K/Akt/mTOR, ii) na presença de inibidores químicos da via 
PI3K/Akt/mTOR e com estimulação exógena da via canónica do NF-κB e iii) na presença combinada 
de inibidores químicos da via PI3K/Akt/mTOR e da via canónica do NF-κB. Os efeitos observados 
foram ainda comparados entre modelos celulares de PTC com diferentes contextos genéticos.  
A nível da análise da atividade transcricional do NF-κB, foi verificado um aumento da expressão 
de um alvo transcricional, em resposta à inibição química da via de sinalização PI3K/Akt/mTOR. 
Curiosamente, o mesmo não se verifica na presença de estimulação exógena da via canónica do NF-κB, 
onde a inibição da via PI3K/Akt/mTOR parece não ter impacto na atividade transcricional do NF-κB. 
Foi no entanto observada uma aparente inconsistência entre a avaliação da ativação de NF-κB  com base 
na sua atividade transcricional e a avaliada através da análise da translocação nuclear da subunidade p65 
deste fator de transcrição. Nesta última situação, os resultados indicam um decréscimo da translocação 
nuclear da subunidade p65 do NF-κB, em resposta à inibição da via de sinalização PI3K/Akt/mTOR. 
Este fenómeno ocorre tanto na ausência de estímulos exógenos da via canónica do NF-κB, como na 
presença dos mesmos. 
No seu conjunto, os resultados deste trabalho sugerem que a via de sinalização PI3K/Akt/mTOR 
poderá influenciar o estado de ativação do fator de transcrição NF-κB. No entanto, devido à aparente 
inconsistência entre a atividade transcricional e a translocação nuclear do NF-κB, não foi possível 
esclarecer se o resultado final do impacto da via de sinalização PI3K/Akt/mTOR no estado de ativação 
deste fator de transcrição é no sentido de inibir ou estimular a sua atividade. Assim, experiências futuras 
serão necessárias de forma a compreender e clarificar esta interação, bem como as suas implicações 
biológicas no contexto do cancro da tiroide. 
Compreender as possíveis interações entre diferentes vias de sinalização envolvidas na 
tumorigénese da tiroide será uma mais valia para o desenvolvimento e adequação de terapêuticas 
dirigidas, particularmente relevante na gestão de doentes com formas agressivas da doença.   
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Cancro papilar da tiroide; via de sinalização PI3K/Akt/mTOR; NF-κB; resistência ao tratamento; 
comunicação entre vias de sinalização. 
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Abstract 
Thyroid cancer is the most frequent endocrine malignancy and its incidence has been rising over 
the past few years.  
Accounting for more than 80% of the cases, the papillary thyroid carcinoma (PTC) is the most 
common subtype of thyroid cancer. In general, PTC patients have a good prognosis after surgery which, 
in specific cases, is followed by radioiodine therapy. However, a subset of patients present advanced 
forms of the disease, with lesions that are frequently unresectable or unresponsive to radioiodine therapy. 
For these patients, no effective alternative treatment exists and new therapeutic options are needed in 
order to increase patients’ survival rate and lifespan. 
Throughout cancer development, several genetic changes occur that deregulate different signalling 
pathways controlling cancer survival, progression and invasion. The most common genetic alterations 
involved in papillary thyroid cancer include BRAFV600E point mutation and RET/PTC rearrangements, 
affecting positively the activity of the pro-tumorigenic MAPK pathway. Nonetheless, RET/PTC 
rearrangements can also activate the PI3K/Akt/mTOR pathway. Besides, RAS activating mutations have 
been detected in PTC patients and, similar to RET/PTC, can signal through both MAPK and 
PI3K/Akt/mTOR pathways. Thus, despite MAPK being considered the main signalling pathway 
involved in thyroid cancer oncogenesis, PI3K/Akt/mTOR can be expected to play an important role 
during this process. Therefore, targeting the PI3K/Akt/mTOR pathway becomes an attractive 
therapeutic option, also in the context of thyroid cancer. 
NF-κB transcription factor has been described as an important anti-apoptotic factor in thyroid 
carcinomas as well as being involved in acquired resistance to therapy. The interplay of NF-κB with 
both MAPK and PI3K/Akt/mTOR pathways has been described in several cancers. Considering that in 
thyroid carcinomas, an interplay between NF-κB and MAPK has been described it may also be relevant 
to analyse a possible crosstalk between NF-κB and PI3K/Akt/mTOR pathways. Thus, aiming to address 
this potential crosstalk, the impact of PI3K/Akt/mTOR in NF-κB activation status was analysed in PTC 
cellular models. NF-κB activity was evaluated in three different conditions: i) upon inhibition of PI3K 
signalling; ii) upon inhibition of PI3K signalling in the presence of exogenous stimulation of the NF-κB 
canonical pathway and iii) upon inhibition of both PI3K and NF-κB signalling.  
Altogether our results suggest the existence of a crosstalk between NF-κB and PI3K/Akt/mTOR 
signalling. However, whether PI3K/Akt/mTOR pathway exerts a positive or negative impact in the 
overall NF-κB activation status as well as the molecular mechanisms behind this interplay and its 
biological significance, require further clarification. 
 
Keywords: 
Papillary thyroid cancer; PI3K/Akt/mTOR pathway; NF-κB; treatment resistance; signalling 
pathways’ crosstalk 
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1. Introduction 
 
1.1. Oncogenesis 
Normal cells evolve progressively into a neoplastic state, through a multistep process called 
oncogenesis. During this process, homeostatic control mechanisms fail, cells grow faster than normal, 
and growth restrains are circumvented. Besides, several genetic changes occur promoting a Darwinian 
advantage to cancer cells clones.1 
By the year of 2000, Hanahan and Weinberg proposed six features, described as hallmarks of 
cancer, which define six essential properties shared by most cancers: sustaining proliferative signalling, 
evading growth suppressors, resisting cell death, enabling replicative immortality, inducing 
angiogenesis and activating invasion and metastasis (figure 1.1). Indeed, cancer cells are characterized 
by excessive cell growth and, therefore, they must sustain proliferative signalling to keep chronic 
proliferation. Throughout this process an excess of oncogene activation occurs and an antiproliferative 
response is induced. Thus, to proliferate without restrictions, cancer cells must evade growth suppressors 
to circumvent anti-proliferative signalling. Furthermore, hyperactive proliferation induces pro-apoptotic 
responses, which need to be circumvented by cancer cells in order to resist cell death. Taking into 
account that cells have a limited number of cell divisions, at a certain time genetic material lost is 
inevitable and cells enter in senescence or even crisis. However, cancer cells can avoid this limitation 
by increasing telomerase activity, which will allow them to replicate endlessly. As cancer cells grow, 
they start to form disorganized tissues, which, like normal tissues, need to evacuate their wastes and 
obtain nutrients and oxygen. Therefore, tumours develop strategies to induce angiogenesis and form 
new vasculature to support their needs. Moreover, at a certain point nutrients and space become limited, 
and cellular stress increases. Thus, cancer cells can also activate a process of invasion and metastasis to 
colonize new places where conditions are more favourable. 2,3  
In 2011 Hanahan and Weinberg revisited their previous report and spread the concept of hallmarks 
of cancer introducing two new emerging hallmarks: reprograming energy metabolism and evading 
immune destruction; and two enabling characteristics: genome instability and mutation and tumour-
promoting inflammation (figure 1.1). The emerging hallmark of reprograming energy metabolism 
reinforced the notion that cancer cells can reprogram their energy metabolism, adapting their needs to 
the environments they are exposed to. In this way, cancer cells can direct their metabolism for glycolysis, 
even in the presence of oxygen, obtaining energy faster than normal cells, as well as the building blocks 
needed to grow and proliferate. The second emerging hallmark proposed, evading immune destruction, 
explains why cancer cells can escape immune surveillance and grow as if immune cells forgot how to 
limit tumour formation. In fact, tumour cells can become invisible to the immune systems and corrupt 
immune cells, so they can cooperate with them, by a process called immunoediting. The emerging 
characteristics are described as essential properties for tumour formation. Accordingly, tumours need 
some genetic instability to promote expansion of clones with selective advantage, as well as a certain 
degree of inflammation, which is a major driver of mutagenic events that could accelerate clones’ 
evolution and also provide bioactive molecules such as growth factors, essential for tumour 
proliferation. 3 
During the multistep oncogenesis, cancer cells adapt a tumour microenvironment composed by 
several elements essential for tumour formation, progression and invasion. This microenvironment is 
different between organs and is composed by cells that support and communicate with cancer cells to 
support their needs.1–3  
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1.2. Thyroid cancer  
Within the endocrine system, thyroid cancer is the most frequent malignancy and its incidence has 
been rising over the past years. 4–9  
The thyroid gland is composed of two different types of cells: the parafollicular C cells responsible 
for calcitonin production; and the epithelial follicular cells responsible for iodide uptake and thyroid 
hormone synthesis.6,10 Thyroid cancer usually develops from the follicular cells, whereas only 3-5% 
arise from the parafollicular cells originating a different type of cancer known as medullary thyroid 
cancer (MTC). 6,10–17 
 Follicular cells give rise to three main different groups of cancer, distinguished by their histological 
architecture and cellular morphology features.6,8,12,17,18 The most common, accounting for more than 
80% of the cases, is called papillary thyroid cancer (PTC) 6,17,19,20 and it is defined for being a well-
differentiated carcinoma (WDTC) and for having a good prognosis.7,21,22 Less frequent, follicular thyroid 
cancer (FTC) is also a well-differentiated carcinoma, however it has a worse prognosis than PTC.12,23 
The anaplastic thyroid cancer (ATC), an undifferentiated carcinoma, is the rarest form of thyroid cancer 
(around 1-3% of all cases), but it is the most aggressive form of all subtypes. 6,8,12,21,24 Moreover, an 
intermediate form between the WDTC and ATC called poorly differentiated thyroid carcinoma (PDTC) 
can also be found, accounting for less than 6% of the cases. Like ATC, PDTC represents an aggressive 
form of thyroid cancer6,10,11,21 
The majority of patients with papillary thyroid cancer are managed successfully and present low 
mortality, after surgery and eventually radioiodine therapy. However, a subset of these patients harbours 
advanced aggressive forms, which are frequently unresectable or unresponsive to radioiodine therapy. 
4,12,17,22,25–27.  For these patients new therapeutic options with more efficient treatments are needed. Thus, 
understanding the molecular mechanisms behind thyroid tumorigenesis would be a relevant asset to 
identify new targets and develop better therapeutic strategies.4–6,9,12,15,22,28 
 
Figure 1.1- Hallmarks of cancer. This figure encompasses the classic hallmarks of cancer along with the two new 
emerging hallmarks and enabling characteristics. The hallmarks of cancer define essential properties for cancer formation, 
development and progression shared by most cancers. Adapted from Hanahan and Weinberg (2011) 3 
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1.3. Gene alterations in thyroid cancer 
Throughout the multistep cancer formation, several genetic changes occur affecting genes 
responsible for major cell survival and proliferation signalling. In fact, thyroid cancer is not an exception 
to the former and results from a gradual accumulation of genetic alterations which frequently lead to an 
excessive activation of the pro-survival MAPK (mitogen-activated protein kinase) pathway, mostly due 
to point mutations or gene rearrangements.4,6,7,9,11,19.  
Different subtypes of thyroid cancer are composed by distinct patterns of gene alterations. The PTC 
group, mutations are mostly related to BRAF (rapidly accelerated fibrosarcoma type-B) point mutations 
(40-60% of the cases) or RET/PTC rearrangements (20% of the cases).24 On the other hand, 40-55% of 
FTC cases are linked with RAS (rat sarcoma) point mutations or in a smaller fraction (30-35%) related 
to PAX8/PPARG rearrangements, or even with PTEN (phosphatase and tensin homolog) or PI3KCA 
gene alterations.7,18,19,21,24,25 Contrasting with the other two subtypes, in ATC, gene rearrangements are 
rare but, in addition to the mutations described above, they also can harbour TP53 and CTNNB1 
mutations.11,24  
1.3.1. BRAF mutations  
BRAF is an intracellular serine-threonine kinase and is related to MAPK pathway.7,11 When 
activated, this protein is translocated to the cell membrane where it will activate its downstream 
effectors.11 In thyroid cancer, this kinase is frequently mutated and associated with the diagnosis of PTC. 
Indeed, the majority of PTC harbours a BRAF point mutation called BRAFV600E, which is characterized 
by a substitution of a thymine for an adenine at codon 600 at BRAF gene. This results in an amino acid 
substitution of a valine-to-glutamine, which in terms of protein activity, leads to constitutive activation 
of BRAF protein, resulting in a downstream activation of MAPK pathway independent of RAS 
activation.6,7,9,11,21,28 Furthermore, negative feedback mechanisms responsible for controlling this 
pathway are ineffective in the presence of this downstream activation.17  
Several lines of evidence suggest BRAF mutations are involved in initiation of thyroid cancer. The 
fact that BRAF mutations could be found in microcarcinomas as well as in more advanced forms, 
supports this idea that BRAF mutations are an early event in the process of thyroid oncogenesis. 6,11  
1.3.2. RET/PTC rearrangements 
RET is a proto-oncogene well-conserved between species that encodes a tyrosine kinase receptor.7,29 
In thyroid cells, RET gene is normally expressed in parafollicular C cells, but not in the follicular ones.7 
However, a hybrid protein can be formed through the fusion between oncogenic RET protein and a 
protein that is constitutively expressed in thyroid follicular cells, leading to the ectopic RET expression 
in these cells. RET/PTC rearrangements occur through this process, due to a chromosomal translocation. 
More specifically, the carboxyl domain of RET kinase domain is fused to the amino domain of a protein 
constitutively expressed in follicular thyrocytes. This phenomenon results in autophosphorylation of 
RET protein in thyroid follicular cells and, consequently, leads to its constitutive activation.18,24,29  
RET/PTC gene rearrangements  by allowing constitutive activation of RET tyrosine kinase domain 
in thyroid follicular cells, promote an activation of both MAPK and PI3K/Akt/mTOR pathways in these 
cells.7,11,25,29  
These rearrangements are more frequent in PTC subtype, being the RET/PTC1 and RET/PTC3 the 
most common.7,18,21  
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1.3.3. RAS point mutations  
RAS is a family of proto-oncogenes, encoding small GTPases.18,21,30 These proteins are located at 
the cytoplasmatic surface of the cell membrane and after receiving signals from tyrosine kinase 
receptors, for example, they transmit a signal to its downstream effectors that frequently activate MAPK 
and PI3K/Akt/mTOR pathways.6,9,11,18,21  
In thyroid cancer, activating point mutations of all three RAS genes (HRAS, KRAS, NRAS) were 
detected, being those in NRAS gene the most frequent. Contrary to BRAF or RET/PTC alterations, RAS 
point mutations are mostly related to FTC. However, 10-20% of PTC cases, also harbour these 
alterations. 7,10,11,18,21 
1.3.4. PAX8/PPARγ rearrangements 
PAX8 gene encodes for a transcription factor that belongs to the paired box family. 11,12,31This gene 
is critical for normal thyroid development and function, as well as for the expression of many thyroid-
specific genes. On the other hand, PPARG gene encodes PPARγ protein, which is also a transcription 
factor but belonging to the nuclear receptor family. Its main function is related with lipid metabolism 
and adipogenesis, though there are pieces of evidences pointing out PPARγ as a tumour suppressor.31 
The fusion between PAX8 and PPARG genes leads to PAX8/PPARγ rearrangements, which like 
RET/PTC rearrangements are also a result of a chromosomal translocation. However, contrary to 
RET/PTC, PAX8/ PPARγ rearrangements are more frequently found in FTC patients.11,21,31 
1.4. Signalling pathways in thyroid cancer 
Thyroid cancer has been described by several researchers as a “MAPK cancer”.4,6,7,9,11,32 This 
signalling pathway plays the most important role in thyroid tumorigenesis, since early events in thyroid 
cancer are frequently related with MAPK signalling alterations.4,6,10,11 Nonetheless, thyroid cancer is 
characterized by mutations with the ability to activate both MAPK and PI3K/Akt/mTOR signalling, as 
previously described. In fact, in the past years with the advances in genetics and molecular biology, 
PI3K/Akt/mTOR pathway has also been recognized as an important player in thyroid cancer 
pathogenesis and progression, particularly in FTC and ATC but also in PTC.6,7,12,15,16,25,33,34  
Constitutive activation of PI3K/Akt/mTOR pathway has been shown to confer predisposition for 
thyroid cancer in Cowden’s syndrome.35 However, PI3K signalling activation by itself is not sufficient 
to promote thyroid transformation, suggesting that other alterations are needed.6,36 Even though, 
mutations affecting PI3KCA gene are relatively common in FTC and ATC, as well as amplifications of 
this gene. In PTC, mutations in PI3KCA gene, or in other factors affecting different components of PI3K 
signalling, are rare.6,7,10,17,25,33 Nevertheless, it is believed that this signalling pathway is involved in PTC 
progression to more advanced forms, or even in the transition of ATC from PTC. 9 Moreover, PTC is 
characterized by harbouring alterations with the ability to affect both MAPK and PI3K/Akt/mTOR 
pathways.12 These facts, along with the fact of MAPK pathway being able to communicate and activate 
PI3K signalling, led researchers in the past years to look at PI3K as an appealing target in the 
development of novel therapies, toward advanced forms of thyroid cancer.17 
 
1.4.1. MAPK signalling pathway 
Like many other signalling pathways, MAPK signalling is a double-edge sword for being essential 
for normal cell survival and maintenance as well as for tumour formation and progression. 
MAPK constitute a family of serine/threonine protein kinases with four parallel and independent 
pathways.9,37 The classical MAPK pathway is composed by the protein kinases RAF (rapidly accelerated 
fibrosarcoma), MEK (MAPK/Erk kinase) and ERK ( extracellular signal-regulated kinase), also referred 
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as MAPK kinase kinase, MAPK kinase and MAPK, respectively. This pathway is considered a 
conserved intracellular signal-transduction pathway, which is often hyperactivated in cancer. 6,38,39  
Upon external stimuli, activation of plasma membrane receptors occurs, leading to the recruitment 
of GEF (guanine nucleotide exchange factors) by adaptor proteins. GEF will in turn, activate RAS 
proteins by exchanging GDP (guanosine diphosphate) for GTP (guanosine triphosphate). Active RAS 
(GTP-bound) recruits RAF proteins to the cell membrane where they will become active. Once RAF 
proteins become active, a series of phosphorylation events take place resulting in ERK activation, which 
will phosphorylate several substrates in the cytoplasm, mitochondria, Golgi, endoplasmic reticulum and 
nucleus (figure 1.2). The result of this signalling cascade will be the regulation of several proteins and 
transcription factors related with cell proliferation, survival, differentiation, apoptosis, metabolism and 
immune response.6,17,38,39  
MAPK pathway is tightly regulated under non-pathological conditions by phosphatases and by 
bidirectional communications with other signalling pathways such as PI3K/Akt/mTOR. Furthermore, 
highly complex regulatory events present in both cytoplasm and nucleus allow a spatial and temporal 
fine tune of MAPK signalling intensity. However, during cancer formation and progression, this 
regulation is corrupted and MAPK signalling suffers an abnormal hyperactivation, feeding the needs of 
cancerous cells.37 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2- Classic MAPK signalling pathway. MAPK pathway is a signalling pathway essential for normal cell 
maintenance and survival and its abnormal activity is frequently involved in cancer. The classic pathway involves RAS 
activation and signals through three main proteins: RAF, MEK, ERK. After ERK phosphorylation, this protein becomes active 
and regulates the activity of several proteins responsible for cellular functions such as survival, proliferation and apoptosis. 
Adapted from Burotto et al. (2014).37  
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1.4.2. PI3K/Akt/mTOR signalling pathway 
PI3K/Akt/mTOR, like MAPK pathway, an evolutionary conserved signalling pathway, is 
recognized for being crucial in both normal cell function and survival and cancer development. 15,40 This 
pathway controls many cellular processes including growth, proliferation, survival, metabolism, 
apoptosis, cell motility and migration. Interestingly, many of these functions are related with the 
essential features for tumour formation and progression, previously defined as hallmarks of cancer. 
Indeed, alterations in normal PI3K/Akt/mTOR signalling pathway, hereafter called PI3K signalling, are 
frequently connected with cell transformation, tumour development and progression and also with 
metastasis.6,9,25,15,40,41 
As its name suggests, this signalling pathway is composed by three main proteins: PI3K 
(phosphatidylinositol-4,5-bisphosphate 3-kinase), Akt (also known as protein kinase B) and mTOR 
(mammalian target of rapamycin).15 PI3K is a family of intracellular lipid kinases responsible for 
catalysing the phosphorylation of phosphatidylinositols and phosphoinositides.9,25,15,40,41 According to 
lipid substrate specificity and structure regulation, PI3K proteins can be divided into three different 
classes, in which class I is the most studied.6,40,42 Class I PI3K can be further divided into two different 
subclasses according to the signal receptors that activate them.40 However, besides all classes of PI3K 
being related with cell growth and regulation, once class IA is the most related to cancer development, 
for the scope of this work class IA will be the only PI3K class considered.6,15,40,42 
Class IA PI3K is composed by heterodimers that are normally activated in response to RTK 
(receptor tyrosine kinase), by direct interaction or through adaptor proteins such as IRS (insulin receptor 
substrate).25 Moreover, this class of PI3K could also be activated by direct interaction with active RAS 
since they have a RAS binding domain.6 These heterodimers are composed by a regulatory and a 
catalytic subunit. 6,41,42 The regulatory subunit controls activation of catalytic subunit and has three 
isoforms: p85α, p85β and p55γ. The catalytic subunit is responsible for the production of PIP3 
(phosphatidylinositol 3,4,5-triphosphate) and also exists as three isoforms: p110α, p110β and p110δ.40 
Notably, in cancer context, constitutive activating mutations of the PI3K class IA subunit genes have 
been described, namely in the PI3KCA gene which encodes for the p110α catalytic isoform. More 
specifically, PI3KCA is frequently mutated in human cancer, in which around 80% of mutations occurs 
in one of the three hot spot regions: E542K, E545K or K1047R. This results in catalytic subunit 
activation, independently of the regulatory one, leading to an increase of PI3K signalling activity.6,25,40 
Upon activation, PI3K heterodimers are recruited to their lipid substrates in the plasma membrane 
where the catalytic subunit will be activated, leading to the production of PIP3 second messenger.6,41 
This action is reversed by the phosphatase PTEN, which dephosphorylates PIP3 into PIP2 
(phosphatidylinositol 3,4,5-diphosphate). After being produced, PIP3 binds to PH (pleckstrin 
homology) domains of different target proteins, recruiting them to the plasma membrane. Two of those 
proteins are Akt and PDK1 (3-phosphoinositide-dependent protein kinase 1), which are important 
downstream effectors of PI3K signalling. Co-recruitment of Akt and PDK1 will promote Akt 
phosphorylation by PDK1 at threonine 308 (Thr308), which along with phosphorylation at serine 473 
(Ser473) by mTORC2 (mammalian target of rapamycin complex 2), induce full activation of Akt.  
6,25,30,33,40 
Akt is a serine/threonine kinase that presents three isoforms with distinct patterns of expression. 
Akt1 and Akt2 are expressed in almost all cells, whereas Akt3 is only found in the brain, heart and 
kidneys.6,25,33,40 After being fully activated, Akt phosphorylate several substrates within the cytoplasm 
or into the nucleus.9 Some of these substrates are GSK-3 (glycogen synthase kinase), FOXO (forkhead 
box O), PRAS40 (proline-rich Akt substrate of 40 kDa) and TSC2 (tuberous sclerosis protein 2).15,30,33,40 
Phosphorylation of FOXO and GSK-3 will prevent cell cycle arrest and pro-apoptotic signalling.40 TSC2 
phosphorylation will relief its inhibition on Rheb (ras homolog enriched in brain) GTPase, which in turn 
leads to mTORC1 (mammalian target of rapamycin complex 1) activation. Furthermore, 
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phosphorylation of PRAS40 avoids its negative regulation on mTORC1, favouring once again mTORC1 
activity.15,33,40 
mTOR is a serine threonine/serine kinase ubiquitously expressed in mammals responsible for 
controlling protein synthesis necessary for cell growth and metabolism.6,41 mTOR kinase is present in 
two functionally different complexes: mTORC1 and mTORC2.6,30 mTORC1 is characterized for being 
sensitive to Rapamycin and besides mTOR kinase, it is composed by RAPTOR (regulatory-associated 
protein of mTOR), mLST8( mammalian lethal with SEC13 protein 8) and negative regulators PRAS40 
and DEPTOR (DEP domain-containing mTOR-interacting protein).30,41 This complex is activated by 
PI3K/Akt signalling and regulates protein biosynthesis through the phosphorylation of S6K (70 kDa 
ribosomal protein S6 kinase, also known as p70S6K) and 4E-BP1 (eIF-4E binding protein 1).30,33,41  
Phosphorylation of S6K will promote its activity, leading to phosphorylation and activation of S6 
protein, responsible for promoting protein synthesis of some elements important for cell growth such as 
ribosomal proteins and elongation factors. For this reason, phospho-S6 (p-S6) is frequently used in 
experiments as an indicator of mTORC1 activation. On the other hand, phosphorylation of 4E-BP1 
blocks its activity, preventing its effects on protein translation inhibition.30 mTORC2 activation seems 
to be more related with growth factors, and its best characterized activity is the phosphorylation of Akt 
at Ser473.25,30 However, it seems that mTORC2 is also responsible for phosphorylating PKCα (protein 
kinase c) and paxillin, as well as for regulating small GTPases .22,30 In terms of composition, like 
mTORC1 , mTORC2 is composed by mTOR kinase,  mLST8 and DEPTOR. Additionally, mTORC2 is 
further composed by RICTOR (rapamycin-insensitive companion of mTOR), mSIN1 (stress-activated 
map kinase-interacting protein 1), PROTOR (protein observed with rictor)  and Hsp70 (70 kD heat 
shock protein).25,30,41 
In summary, activation of PI3K leads to the production of a second messenger PIP3, which in turn 
recruits Akt to the plasmatic membrane allowing its activation by PDK1 and mTORC2. Once activated, 
Akt phosphorylates and inhibits TSC2, relieving Rheb GTPase activity and promoting mTORC1 
activity. With this, activity of S6K is promoted and 4E-BP1 is blocked, resulting in translation of several 
proteins essential for cell growth and metabolism. (figure 1.3). 9,15,25,30,33,41 
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Figure 1.3- PI3K/Akt/mTOR signalling pathway. PI3K/Akt/mTOR pathway is essential for normal cell function and 
survival and its dysregulation is often seen in cancer. After a stimulatory event, PI3K is activated and through the production 
of PIP3, recruits Akt to the cell’s membrane, where it will be activated. After activation, Akt relieves Rheb inhibition, 
promoting mTOR activation. Once activated, mTOR will regulate protein translation and cell’s growth, through S6K 
stimulation and 4E-BP1 inhibition. Adapted from Robbins et al. (2016).33 
1.5. NF-κB (Nuclear factor kappa-light-chain-enhancer of activated B cells) 
Since its discovery in 1986, NF-κB has been extensively studied due to its involvement in a 
multitude of diseases, including cancer.5,43 This transcription factor is responsible for the control of 
several biological aspects such as immune and inflammatory responses or even cell growth and 
apoptosis. 13,14,44,45 
NF-κB is conserved among species and is ubiquitously expressed, although its function varies 
according the cell type it is expressed.43,45 Moreover, in mammals NF-κB is frequently viewed as a 
family of transcription factors composed by five members that form homodimers or heterodimers among 
each other: p65 (RELA), RELB, c-Rel, NF-κB1 (also known as p105) and NF-κB2 (also known as 
p100).46–48 These members can be further divided into two classes according to their mode of synthesis 
and transactivation properties. The first class is characterized by proteins synthetized in their mature 
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forms and includes p65, RELB and c-Rel. The second class is composed by NF-κB1 and NF-κB2 which 
are synthetized as large precursors and are further processed into p50 and p52, respectively.49 In 
common, both classes contain a highly conserved REL homology domain (RHD) essential for 
dimerization, DNA binding and association with inhibitory proteins.48,50 
 The way NF-κB dimers are activated can be viewed as two main pathways: the canonical and the 
non-canonical pathway. Canonical pathway is triggered in response to numerous stimuli, involving pro-
inflammatory cytokines such as TNFα (tumour necrosis factor α) and depends on the activity of IKKγ 
regulatory subunit as well as the catalytic IKKβ subunit. This pathway involves preferentially the 
heterodimer p65/p50 and is responsible for controlling several aspects of cell growth and 
inflammation.13,14,46–49,51 On the other hand, non-canonical pathway involves preferentially p52/RELB 
heterodimers, being triggered  in a more restricted way by some cytokines of TNF super family and 
depending on the activity of NF-κB-inducing kinase (NIK) and IKKα.46–49,52.  Also, non-canonical 
pathway functions are more related with immunity aspects, including the regulation of lymphoid 
organogenesis and B-cell maturation, for example.51,52 Furthermore, while canonical NF-κB activation 
is dependent on degradation of its inhibitor ( inhibitor of κB, IκB), the non-canonical NF-κB is related 
with a mechanism involving p100 processing.52 
 In the absence of stimuli, NF-κB canonical dimers are normally present in the cytoplasm as an 
inactive form for being held to their inhibitor IκB.5,13,14,44,47 After a stimulatory event, activation of a 
protein kinase complex called IKK (IκB kinase) occurs. This complex is composed by IKKα and IKKβ 
catalytic subunits in combination with a regulatory subunit IKKγ (also called NEMO) and its activation 
leads to IκB phosphorylation and, consequently, to its degradation, resulting in the release and activation 
of NF-κB dimers.13,14,45–47,49 Upon release, the nuclear localization signal (NLS) of NF-κB dimers is 
exposed and NF-κB is translocated into the nucleus promoting the transcription of several target genes 
(figure 1.4). 49 
 
Figure 1.4- Canonical and non-canonical pathways of NF-κB.  NF-κB transcription factor regulates several biological 
aspects such as inflammation and cell’s growth and apoptosis, which are essential during cancer’s formation. NF-κB is 
normally retained in the cytoplasm for being bound to its repressor IκB. Upon stimuli, IκB is phosphorylated by IKK, resulting 
in its proteasomal degradation. Canonical pathway involves the heterodimer p65/p50 and depends on IKKγ regulatory subunit 
activity. Non-canonical pathway is more related with NIK and IKKα activity and involves preferentially the heterodimer 
p52/ReLB. Adapted from Shao-Cong Sun (2011). 52 
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1.5.1. NF-κB in thyroid cancer 
Dysregulation of NF-κB signalling has been implicated in many cancers. In the particular case of 
thyroid cancer, activation of NF-κB was found in PTC, FTC and ATC, suggesting that this transcription 
factor has an important role during thyroid cancer formation.9,13,35 In fact, many authors have gathered 
evidence that NF-κB contributes to thyroid tumorigenesis. The first evidence was exposed by Visconti 
et al. in 1997 53, where they demonstrated that NF-κB canonical activation occurs during thyroid cancer 
development.14,53 Later, in 2004, Pacifico 13 and his group demonstrated that NF-κB contributes to 
thyroid oncogenesis, by inhibiting the apoptotic program. Moreover, this group also proposed that 
chronic activation of NF-κB in thyroid cancer cells could be due to defects in IκBα regulation or even 
by production of autocrine factors that stimulate this signalling.13 In line with the previous references, 
in 2017 Faria et al.4 proposed that in PTC cell lines RAC1b overexpression signals through NF-κB, 
resulting in apoptosis resistance.  
In the context of normal thyroid physiology, in 2016, a publication from Reale’s group 45 has shown 
that NF-κB signalling is required for normal function and structure of thyroid cells. Thus, despite being 
crucial for normal thyroid cell survival and maintenance, NF-κB signalling dysregulation plays an 
important role during thyroid cancer formation, leading to an anti-apoptotic behaviour.4,5,9,13,14,45 
Furthermore, NF-κB is frequently related with treatment resistance and with aggressive behaviour of 
thyroid carcinomas.5,35  
1.6. Crosstalk between signalling pathways in papillary thyroid carcinomas 
Once mutations characterizing PTC are mostly related with aberrant activation of MAPK 
signalling6,12,17, inhibition of this pathway would be an obvious therapeutic choice for those patients with 
advanced disease. However, the use of MAPK pathway inhibitors, such as MEK or BRAF inhibitors, 
are related with undesirable side effects and most patients develop resistance to treatment after a short 
period of time.26,54,55 Therefore, other molecular pathways must be acting in concert to promote tumour 
survival and resistance to therapy, in these cases. 
 Roelli et al. (2017) 20 have shown that in aggressive PTC, activation of PI3K signalling conferred 
resistance to BRAF inhibitors and that this resistance was overcome with a PI3K inhibitor combination. 
In line with that, another study had established that thyroid carcinoma’s migration and proliferation is 
in part mediated by both Ras/MAPK and PI3K/Akt/mTOR pathways and that these pathways 
communicate with each other. Moreover, the same authors suggested that the interplay between both 
pathways results in cross-activation or inhibition processes, depending on the cell type. 34 
When treatment resistance is discussed in the context of thyroid cancer one of the most mentioned 
elements is the NF-κB transcription factor. In 2006, a study has demonstrated that accumulation of 
BRAFV600E protein promote an increase of IκBα degradation, and consequently to NF-κB activation. 
Also, CRAF, a protein that transmits signals from RAS to MEK, has been indicated as an activator of 
NF-κB.56 
In summary, it seems that MAPK can communicate with both PI3K/Akt/mTOR and NF-κB, being 
this phenomenon intrinsically related with treatment resistance. However, potential crosstalk between 
PI3K/Akt/mTOR and NF-κB pathways remains to be elucidated.  
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2. Aim of the project 
This work aims to address the potential interplay between the transcription factor NF-κB and the 
signalling pathway PI3K/Akt/mTOR in papillary thyroid cancer cell lines. For this purpose, a PTC cell 
line harbouring a mutation in PI3KCA gene that leads to constitutive activation of PI3K protein was 
used. 
The main tasks were to evaluate NF-κB activity upon inhibition of PI3K/Akt/mTOR pathway: 
(i) by using chemical inhibitors for PI3K and/or mTORC1. 
(ii) by blocking PI3K signalling in the presence of exogenous stimulation of the canonical 
NF-κB pathway.  
(iii) by addressing the impact of PI3K signalling on NF-κB activity in the presence of 
chemical inhibition of NF-κB canonical pathway. 
To further evaluate the impact of PI3K signalling on NF-κB activity, cellular systems with different 
signalling backgrounds were used and results were compared. 
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3. Materials and Methods 
3.1. Cell culture and reagents 
In this study, the human papillary thyroid carcinoma cell lines K1, TPC1 and BCPAP were used. 
These cell lines harbour different genetic backgrounds as shown in table 3.I. 
K1 cells were maintained in Dulbecco’s modified eagle medium/nutrient mixture F-12 
(DMEM:F12 1:1, Lonza). TPC1 and BCPAP cells were cultured in RPMI 1640 medium (Lonza). All 
mediums were supplemented with 10% (v/v) of foetal bovine serum (FBS, Biochrom) and 1% (v/v) 
glutamine (Gibco). All cells were maintained at 37ºC in an humified environment with a 5% CO2 
atmosphere. When cells reached the optimum confluence (80-100%), they were washed with 
Dulbecco’s phosphate buffered saline 1x (DPBS1x, Lonza), detached by incubation at 37ºC with 
trypsin-EDTA (ethylenediamine tetraacetic acid, Invitrogen) and subcultured in a new flask at a 
confluency of 25%. 
Cells were treated with PI3K inhibitor Ly294002 (Sigma-Aldrich), mTORC1 inhibitor Rapamycin, 
PI3K/mTOR dual inhibitor BEZ235 (Sigma-Aldrich), IKKα/β inhibitor BMS-345541 and human 
Tumour Factor Necrosis α (hTNFα, R&D Systems), using the conditions described in Table 3.II. To 
perform these treatments, cells were seeded in 12-well plates (Thermo Scientific) at 60% confluency and 
synchronized for 24 h in starvation (serum free) medium, after they became adherent. Then, medium 
was replaced with fresh supplemented medium or fresh starvation medium, depending on the intended 
treatment. At the end, cells were used for RNA extraction (3.2) or for western blot analysis (3.5). 
Table 3.1- PTC-derived cell lines major genetic alterations 
 
 
 
 
 
 
Table 3.II - PI3K/Akt/mTOR signalling pathway inhibitors conditions 
Reagents Final concentration Time of treatment (hours) 
Ly294002 50 µM 6 
Rapamycin 100 nM 6 or 24 
BEZ235 100 nM 6 
TNFα 100 nM 1 
BMS-34554 10 µM 7 
3.2. RNA extraction and complementary DNA (cDNA) synthesis 
Cells were lysed with tripleXtractor reagent (Grisp) and RNA was extracted according to the 
manufacturer’s protocol.  During protocol procedures, an Eppendorf centrifuge 5415R was used. For 
each sample, RNA concentration was measured in nanodrop™ 2000 spectrophotometer (Thermo 
Scientific). 
After RNA extraction, cDNA was synthetized from 1 µg of RNA.  Firstly, the RNA sample, 0.1 µL 
of random primers (3 µg/µL) (Roche), 0.8 µL of deoxynucleotides (dNTPs mix: dATP, dCTP, dGTP, 
dTTP, 25 mM each) and purified water (ddH2O) up to 15 µL were mixed together and incubated at 65ºC 
during 10 min. This initial step aimed the removal of RNA secondary structures which could affect 
cDNA synthesis efficiency. After this step, a mix made with 4 µL of reverse transcriptase buffer 5x 
(Thermo Scientific), 0.5 µL reverse transcriptase (200 U/µL) (Thermo Scientific) and 0.5 µL 
RNAaseOut™ ribonuclease (40 U/µL) (Invitrogen), was added to each sample. Then, cDNA synthesis 
Cell line Major genetic alterations 
K1 PI3KE542E, BRAFV600E, TP53R213R 
TPC1 RET/PTC1 
BCPAP BRAFV600E, TP53D259Y 
 13 
 
was performed using the basic program described in Table 3.III, in a 2720 thermal cycler (Applied 
Biosystems). 
Table 3.III - cDNA synthesis conditions 
 
 
 
 
 
 
3.3. Reverse transcription polymerase chain reaction (RT-PCR) 
RT-PCR amplification was performed to control IκBα gene expression. Specific primers for IκBα 
amplification (F-forward, R-reverse) IκBα human F (5’- CTACACCTTGCCTGTGAGCA), IκBα 
human R (5’-CCCCACACTTCAACAGGAGT), were used, originating a 280 base pairs (bp) PCR 
product. 
 A reaction mixture containing 0.25 µL of specific primers, along with 12.5 µL of PCR buffer (see 
supplementary table I), 0.1 µL of Taq polymerase (5 U/µL) (Nzytech) and 1 µL of cDNA sample, was 
prepared. The reaction took place in a 2720 thermal cycler (Applied Biosystems) using the basic program 
described in Table 3.IV. 
Table 3.IV - IκBα RT-PCR amplification conditions 
Stage Temperature ºC Time  Cycles 
Initial denaturation 95 5 min 1 
Denaturation 95 30 seconds 
24 Annealing 60 30 seconds 
Elongation 72 30 seconds 
Final elongation 72 3 min 1 
Inactivation and Cooling 4 ∞ 1 
 
The RT-PCR products were analysed by electrophoresis on a 2% agarose gel made with Tris-
Borate-EDTA buffer 1x (TBE 1x) diluted in distilled water from TBE 10x (Grisp) and stained with 
0,05% (v/v) ethidium bromide (Invitrogen). Gel electrophoresis was performed in a Biorad sub-cell GT 
electrophoresis chamber at 130 mV for 30 minutes, and the gel was visualized upon exposer to UV light 
in VWR Genosmart 1107 transilluminator.  
3.4. Quantitative reverse transcription polymerase chain reaction (RT-qPCR) 
IκBα (target gene) mRNA expression, was quantified by RT-qPCR in the LightCycler® 480 II 
(Roche) using the xpert fast SYBR mastermix (Grisp). TATA-binding protein (TBP) expression was 
used as reference. RT-qPCR was performed according to manufacturer’s protocol and reaction mixtures 
were prepared using 5 µL of xpert fast SYBR mastermix, 0.25 µL of each primer, 1 µL of cDNA sample 
in ddH2O to a final volume of 10 µL.  The sequence of specific primers used for IκBα and TBP 
amplification were as follow:  IκBα human F (5’- CTACACCTTGCCTGTGAGCA) IκBα human R (5’-
GACACGTGTGGCCATTGTAG), TBP human F (5’-TGCACAGGAGCCAAGAGTGAA), TBP 
human R (5’-CACATCACAGCTCCCCACCA). 
IκBα expression was normalized to TBP and mRNA relative quantification was determined using 
the 2-∆∆Ct method (the efficiency of both target and reference genes were similar, nearly 100%). 
Stage Temperature ºC Time  
Annealing 25 10 min 
Elongation 42 60 min 
Inactivation 70 10 min 
Cooling 4 ∞ 
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3.5. Western Blot 
PI3K/Akt/mTOR pathway activation status was evaluated by western blot, through monitorization 
of phospho-S6 (p-S6) protein. β-actin was used as an endogenous control. 
Protein extracts were obtained using 50 µL of lysis buffer (see supplementary table II) and 
denatured during 10 min at 95ºC. 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was performed to separate proteins of each 
sample, by adding equivalent amounts of protein extracts to the gel. The SDS-PAGE gel consisted of 
two distinct gels: a lower 10% polyacrylamide gel (resolving) and an upper 4% polyacrylamide gel 
(stacking) (see supplementary table II). Electrophoresis was carried in SDS-PAGE buffer 1x at 20 mA 
per gel, during approximately 1h. Subsequently, proteins were transferred into polyvinylidene difluoride 
(PVDF) membranes (Bio-Rad), previously activated in methanol, using a blot electrophoresis transfer 
cell (Bio-Rad) for 1 h at 100 V. Then, membranes were stained with coomassie blue and washed: firstly, 
with a destain solution and then with tris-buffered saline 0.05% triton x-100 (TBST) (see supplementary 
table II).  
Membranes aimed for detection of the endogenous control β-actin, were incubated for 1 h in a 
solution of TBST with 5 % (w/v) non-fat milk (TBST milk) to avoid unspecific bindings and then, 
incubated overnight at 4 ºC with mouse anti-β-actin (Sigma-Aldrich) in a 1:10000 dilution in TBST 
milk.  Membranes aimed for detection of phosphorylated S6 protein were incubated overnight at 4 ºC 
with the primary antibody rabbit anti-pS6 (Cell Signaling) in TBST in a 1:2000 dilution. Finally, after 
a washing step with TBST, membranes were incubated for 1h at room temperature (RT) with horseradish 
peroxidase-conjugated (HRP) specific secondary antibodies: anti-mouse (1:5000) (Thermo Scientific) 
and anti-rabbit (1:5000) (Thermo Scientific), all diluted in TBST milk. 
Protein bands were detected by exposure on autoradiographic films after luminol-based enhanced 
chemiluminescence (ECL) (see supplementary table II). 
3.6. Immunofluorescence 
Analyses of NF-κB nuclear translocation were assessed by immunofluorescence technique. For this 
purpose, K1 cells grown on coverslips (10 mm x 10 mm) in a 12-well plate and were subjected to 
treatment with different drugs as described above.  
Cells were washed in PBS 1x (Lonza) and fixed in paraformaldehyde 4% (v/v) for 30 min at RT. 
Two steps of permeabilization were performed aiming the permeabilization of plasmatic and nuclear 
membranes, respectively: first cells were incubated with PBS-triton x-100 (PBST) 0,5% (v/v) for 15 
min at RT and then were followed by an incubation with methanol for 10 min at -20ºC. Subsequently, 
cells were washed three times during 5min with PBST 0.05% (v/v) and incubated overnight at 4 ºC with 
the MUL1 polyclonal primary antibody rabbit anti-NF-κB p65 NLS (Thermo Scientific) at a 1:750 
dilution. Then, cells were incubated with secondary antibody goat anti-rabbit Alexa Fluor 532 (Life 
Technologies; 1:500 dilution) for 30 min, after being washed with PBST 0.05% (v/v) three times for 5 
min. Cells were washed again three times for 5 min with PBST 0.05% (v/v) and nucleus were stained 
with DAPI, following a final fixation step with paraformaldehyde 4% (v/v) for 15min.  Coverslips were 
washed with PBST 0.05% (v/v), mounted in a microscope slide with VectaShield medium and sealed 
with nail polish. Images were recorded in a Leica TCS-SPE confocal microscope with 405 nm and 532 
nm laser lines and processed in ImageJ software. 
3.7. Statistical analysis 
Graphpad Prim 5 software (San Diego, USA) was used to perform statistical analysis. The statistical 
analysis and the evaluation of statistical significance between results were performed using an unpaired 
one-tailed or two-tailed Student’s t-test. Values were expressed as mean with its respective standard 
deviation (SD). Significant results were accepted as p<0,05. 
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4. Results 
4.1. PI3K signalling inhibition is associated with an increase of NF-κB activation readout in K1 cells 
In order to evaluate if there was a potential interplay between NF-κB and PI3K/Akt/mTOR pathway 
in K1 cells, we first analysed the effects of PI3K/Akt/mTOR pathway inhibition on IκBα mRNA levels, 
here used as a readout for NF-κB transcriptional activity. Among several approaches to monitor the NF-
κB activation status, we monitored the transcriptional levels of a target gene by RT-qPCR. Bottero et. 
al showed that IκBα mRNA levels perfectly correlate with the activation of NF-κB in several cellular 
models, indicating that quantification of IκBα is a valid readout of NF-κB activation. Indeed, besides 
being NF-κB repressor, IκBα is under NF-κB transcriptional control and is one of the genes most rapidly 
transcribed after NF-κB is activated.52 For this reason, we decided to use IκBα as a reporter for NF-κB 
activation. 
Inhibition of PI3K signalling was performed using three different approaches. The first consisted 
in the use of Ly294002, which is considered a potent chemical inhibitor of PI3K protein.36 The second, 
was directed to a downstream PI3K signalling event and was performed with Rapamycin, which is a 
mTORC1 chemical inhibitor.57,58 Finally, the last approach consisted in a dual inhibition of PI3K and 
mTOR proteins, using the dual inhibitor BEZ23559 or a combination of Ly294002 and Rapamycin. 
Controls were obtained from cells cultured in the same conditions but treated in the absence of drugs 
with dimethyl sulfoxide (DMSO), the vehicle used for drug’s dilution. 
The effects of chemical inhibitors on PI3K/Akt/mTOR pathway were monitored by western blot. 
For this purpose, β-actin was used as a control to document equal amounts of protein loaded on the gel 
and p-S6 as an indicator of PI3K/Akt/mTOR pathway activation status. As shown in figure 4.1A, all 
inhibitors decreased p-S6 expression, being this effect more notorious with Rapamycin inhibitor. 
Under these experimental conditions, a RT-qPCR was performed to measure the relative mRNA 
levels of IκBα in response to the chemical inhibitors of PI3K signalling. For each assay, data obtained 
with drug treatments were normalized to the corresponding control condition. As shown in figure 4.1B, 
all PI3K signalling inhibitors promoted a statistically significant increase in IκBα mRNA levels. 
Comparing to control, PI3K protein inhibition with Ly294002 resulted in a significant (p<0,05) 2,9-fold 
increase of IκBα mRNA levels, which was the greatest increase verified. Inhibition of mTORC1 with 
Rapamycin, resulted in a significant (p<0,05) 1,28-fold increase of IκBα mRNA levels, being the same 
observed with dual inhibition of PI3K and mTOR with either BEZ235 (1.29-fold increase; p<0,05) or 
the combination of Ly294002 and Rapamycin (1.63-fold increase; p<0,05). Collectively, inhibition of 
PI3K/Akt/mTOR pathway increased IκBα mRNA levels, suggesting an increase in NF-κB 
transcriptional activity, which was higher with upstream signalling inhibition. 
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4.2.  Inhibition of PI3K signalling decreases p65 nuclear translocation in K1 cells 
Since NF-κB transcriptional activity depends on its translocation to the nucleus, we decided to 
further investigate if NF-κB nuclear translocation was affected by the presence of PI3K signalling 
inhibitors, in K1 cells. For that, an immunofluorescence was performed using an antibody that binds to 
uncovered NLS region of p65 protein, which is exposed after IκB repressor degradation. p65 protein is 
involved in the canonical pathway of NF-κB, where it usually forms p65/p50 heterodimers. Nuclei were 
stained with DAPI (blue). 
As shown in figure 4.2A, the red signal intensity present in cells’ nuclei appears to be lower upon 
drug treatment, compared to control conditions. This fact is supported in figure 4.2B quantification of 
fluorescence intensity. Moreover, the decrease in nuclear red staining is slightly more pronounced with 
the PI3K inhibitor Ly294002 than with mTORC1 inhibitor Rapamycin or even with the combination of 
both drugs. This suggests that inhibition of PI3K signalling led to a decrease in the active p65 at the 
nucleus, which is more evident when triggered by pathway inhibition upstream of mTOR.  However, 
data correspond to one single experiment and further assays are needed to clarify these results. 
 
 
 
 
 
 
 
Figure 4.1- PI3K signalling inhibition is associated with an increase of NF-κB activation readout in K1 cells. Cells were 
treated with Ly294002 (50 µM), Rapamycin (100 nM), BEZ235 (100 nM) or with a Ly294002 and Rapamycin combination, 
for 6h. (A) Western Blot analysis was performed to monitor PI3K/Akt/mTOR pathway activation status in the presence of its 
chemical inhibitors. Detection of endogenous β-actin served as control of protein expression. (B) Results of IκBα mRNA 
levels by RT-qPCR. The mRNA levels were measured after cells were treated with chemical inhibitors of the 
PI3K/Akt/mTOR pathway. Controls were obtained in the same conditions but treated with DMSO and in the absence of 
inhibitors. Collectively, results show an increase in NF-κB activation readout after PI3K signalling inhibition. Data are mean 
± error bars (SD) of at least three independent experiments. p-values were calculated comparing control with drug treatments, 
using an unpaired one-tailed Student’s t-test. *p≤0.05. 
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4.3. Inhibition of PI3K signalling has no effect on NF-κB transcriptional readout in the presence of 
NF-κB exogenous stimulation 
It is well known that TNFα is one of the triggers for canonical activation of NF-κB pathway.46,51,60 
Thus, to determine if PI3K signalling influenced the canonical activation of NF-κB, PI3K/Akt/mTOR 
signalling pathway was inhibited in the presence of exogenous TNFα and quantification of the 
transcriptional readout for NF-κB activation was performed by RT-qPCR. For this purpose, cells were 
maintained and treated in a starvation medium to guarantee minimal exogenous stimulations. Controls 
were obtained from cells maintained in starvation medium treated with DMSO only. 
 A RT-qPCR was performed to measure the relative mRNA levels of IκBα in response to TNFα, 
TNFα+Ly294002 and TNFα+Rapamycin. For each condition, data were normalized to the control 
condition.  
Figure 4.3 shows the effects of TNFα alone or upon treatment with PI3K/Akt/mTOR pathway 
inhibitors on mRNA levels of NF-κB transcriptional readout. As expected, and in accordance with other 
authors, TNFα promoted a statistically significant (p≤0.0001) 2-fold increase of IκBα relative mRNA 
levels by comparison with the control, suggesting that TNFα triggered NF-κB canonical activation. 
Considering TNFα as a positive control for NF-κB canonical activation, comparison of TNFα alone 
with TNFα in the presence of Ly294002 or Rapamycin showed no significant differences. Thus, at 
transcriptional level, results suggest that in the presence of exogenous activation of NF-κB canonical 
pathway, PI3K signalling inhibition has no effect on NF-κB activational readout. 
Figure 4.2- PI3K signalling inhibition decreases p65 nuclear translocation in K1 cells. K1 cells were treated with 
Ly294002 (50 µM) for 6 h, Rapamycin (100 nM) for 24 h or with both combined. (A) Cells were stained with anti-p65-NLS 
(red) and nuclei were stained with DAPI (blue). Signals were recorded by confocal microscopy. (B) Graph of 
immunofluorescence relative quantification based on fluorescence intensity analysis, obtained by ImageJ software. Data are 
mean ± error bars (SD) of 12 random image sections representative of cell’s nuclei and correspond to three technical replicates 
of a single experiment. p-values were calculated comparing control with drug treatments, using an unpaired two-tailed 
Student’s t-test. ***P≤0.001 **** p≤0.0001.  
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4.4. Inhibition of PI3K signalling in the presence of exogenous activation of NF-κB canonical 
pathway, decreases p65 nuclear translocation in K1 cells 
To further clarify the data obtained by RT-qPCR, nuclear translocation of p65 was accessed by 
immunofluorescence in the presence of PI3K signalling inhibition along with TNFα stimulation. As 
shown in figure 4.4A, nuclear p65 staining was higher upon TNFα stimulation, when compared to 
control, which is consistent with canonical activation of NF-κB by TNFα. In the presence of Ly294002 
or Rapamycin a decrease of p65 staining in nuclei was observed, when compared to TNFα alone. 
Moreover, the effect of Rapamycin inhibitor was more pronounced than Ly294002 and seems to revert 
the effect of TNFα. This suggests that PI3K signalling inhibitors could antagonize TNFα effect on NF-
κB canonical stimulation. Consistently, when fluorescence intensity analysis of immunofluorescence 
staining was performed, all the differences observed in the qualitative analysis were statistically 
significant, as shown in figure 4.4B. Furthermore, Rapamycin not only statistically reverted the effect 
of TNFα, but also its combination with TNFα, resulted in a decrease of nuclear p65 when compared to 
the control condition. Yet, since data were obtained from only two experiments, further assays are 
needed to clarify these results. Even though, collectively, it seems that nuclear translocation of p65 tends 
to increase in the presence of TNFα and that this effect is counteracted by the presence of 
PI3K/Akt/mTOR pathway inhibitors.  
 
 
 
 
Figure 4.3- Inhibition of PI3K signalling has no effect on NF-κB transcriptional readout in the presence of NF-κB exogenous 
stimulation. IκBα mRNA levels were measured by RT-qPCR. Cells were treated with TNFα (100 nM) for 1 h and maintained in a serum 
free medium (starvation). Treatments with Ly294002 (50 µM) for 6 h or with Rapamycin (100 nM) for 24h were performed in the 
presence of TNFα, which was added 1 h before the end of drug incubation times. Control corresponds to starvation medium treated with 
DMSO. TNFα alone promoted an increase in IκBα mRNA levels, while TNFα in combination with PI3K signalling inhibitors, had no 
effect. Data are mean ± error bars (SD) of at least three independent experiments. p-values were calculated comparing control with drug 
treatments, using an unpaired two-tailed Student’s t-test. **** p≤0.0001. ns: not statistically significant. 
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4.5. Inhibition of NF-κB canonical pathway hampers the effect of PI3K inhibition on NF-κB 
activational readout in K1 cells 
As previous reported and in the absence of exogenous stimulation of canonical NF-κB, the most 
notorious effect on the transcriptional readout for NF-κB activation was achieved upon PI3K inhibition 
with Ly294002. Thus, to further clarify that effect, inhibition of PI3K was performed in the presence of 
NF-κB canonical inhibitor BMS-345541.  
Ly294002 effect was evaluated in the absence and in the presence of BMS-345541, which is 
considered a highly selective inhibitor of IKKβ, avoiding in this way canonical NF-κB-dependent 
transcription.61 A RT-qPCR was performed to measure the relative changes in IκBα mRNA levels in 
response to the referred conditions. Controls were obtained upon treatment with DMSO in the absence 
of Ly294002, with or without BMS-345541. For each assay, data were normalized to the respective 
control and different conditions were compared.  
As shown in figure 4.5, the presence of BMS-345541 in Ly294002 treatment partially reverts the 
stimulatory effect of PI3K inhibition on IκBα mRNA levels, indicating that this transcriptional readout 
for NF-κB activation is hampered by the inhibition of NF-κB canonical pathway. 
Figure 4.4- Inhibition of PI3K signalling in the presence of exogenous activation of NF-κB canonical pathway, 
decreases p65 nuclear translocation in K1 cells. Cells were treated with TNFα (100 nM) for 1 h and maintained in a serum 
free medium (starvation). Treatments with Ly294002 (50 µM) for 6 h or with Rapamycin (100 nM) for 24 h were performed 
in the presence of TNF. Control corresponds to starvation medium treated with DMSO only. (A) Cells were stained with anti-
p65-NLS (red) and nuclei were stained with DAPI (blue). Signals were recorded by confocal microscopy. (B) Graph of 
immunofluorescence relative quantification based on fluorescence intensity analysis, obtained by ImageJ software. Data 
are mean ± error bars (SD) of 15 random image sections representative of cell’s nuclei of two independent experiments.  p-
values were calculated comparing control with drug treatments, using an unpaired two-tailed Student’s t-test. **** p≤0.0001. 
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4.6. PI3K signalling inhibition has differential impact on NF-κB transcriptional readout among PTC 
cell lines with different genetic backgrounds   
K1 PTC derived cell line is characterized by BRAFV600E and PI3KCAE542K point mutations, which 
are responsible for constitutive activation of MAPK and PI3K/Akt/mTOR pathways, respectively. Since 
a potential interplay between these two pathways should be considered, two other PTC systems with 
distinct activational profiles of MAPK and PI3K/Akt/mTOR pathways, were analysed. The systems 
used were TPC1 and BCPAP cell lines, which have different genetic backgrounds: TPC1 is 
characterized by a RET/PTC rearrangement, which has the ability to activate both PI3K/Akt/mTOR and 
MAPK pathways, while BCPAP is characterized by a BRAFV600E point mutation, which leads to the 
hiperactivation of MAPK pathway. 
A RT-qPCR was performed to measure IκBα levels after inhibition of PI3K signalling in K1, TPC1 
and BCPAP cell lines. In each assay, data were normalized to control and treatment with different 
inhibitors were compared. As shown in figure 4.6, the PTC models analysed responded differently to 
PI3K/Akt/mTOR pathway inhibition. The most notorious effect on NF-κB transcriptional readout was 
obtained upon treatment with the PI3K inhibitor Ly294002 in K1 cells while only modest or even no 
effects were observed on BCPAP and TPC1 cell lines.  
 
 
 
Figure 4.5- Inhibition of NF-κB canonical pathway hampers the effect of PI3K inhibition on NF-κB activational readout 
in K1 cells. IκBα mRNA levels were measured by RT-qPCR. Cells were treated with Ly294002 (50 µM) for 6 h in two 
different conditions. The first was in the absence of BMS-345541 (w/o BMS-345541) and the second in the presence of BMS-
345541 (w/BMS-345541). BMS-345541 treatment was performed at 10 µM for 7 h. Data show that presence of BMS-345541 
tends to revert Ly294002 stimulatory effect on NF-κB activational readout. Data are mean ± error bars (SD) of at least three 
independent experiments and were normalized to the respective control. p-values were calculated comparing control with drug 
treatments, using an unpaired one-tailed Student’s t-test. *p≤0.05 **p≤0.01. 
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Figure 4.6- PI3K signalling inhibition has differential impact on NF-κB transcriptional readout among PTC cell lines 
with different genetic backgrounds. IκBα mRNA levels were measured by RT-qPCR in K1, TPC1 and BCPAP cell lines, 
after PI3K signalling inhibition. Cells were treated with Ly294002 (50 µM) for 6 h, Rapamycin (100 nM) for 6 h (in K1) or 
for 24 h (in TPC1 and BCPAP), or with BEZ235 (100 nM) for 6 h. Data were normalized to the respective controls and are 
mean ± error bars (SD) of at least two independent experiments, except for BEZ235 treatment in TPC1 cells, which 
corresponds to only one experiment. p-values were calculated comparing control with drug treatments, using an unpaired one-
tailed Student’s t-test. *p≤0.05 **p≤0.01 ***P≤0.001. ns: not statistically significant. 
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5. Discussion  
Over the last years, advances in thyroid cancer diagnosis reflected an increased number of cases 
harbouring this pathology, being the most common type the papillary thyroid cancer.62,63 PTC has 
normally a good prognosis, after thyroidectomy and, eventually, radioiodine therapy.4,27 However, 
concerns with these patients arise when tumours are unresectable or unresponsive to radioiodine, 
resulting in a worse prognosis and decreased lifespan. 4,12,17,25–27 
Since PTC is mostly related with alterations involving the MAPK pathway6,12,17, inhibition of 
MAPK signalling would be an obvious choice for the therapy of aggressive forms. However, in these 
patients, selective inhibitors of the MAPK pathway are frequently linked with resistance to treatment, 
suggesting the presence of a crosstalk with other signalling pathways.26,54,55 The second most important 
signalling pathway involved in thyroid cancer is the PI3K/Akt/mTOR signalling.27,62 Indeed, there are 
evidences pointing out MAPK and PI3K/Akt/mTOR signalling pathways as fundamental for thyroid 
cancer formation and progression.  In line with that, a study carried by Kandil’s group (2013) 54 has 
shown that combination of MEK and PI3K inhibitors that are under clinical trials, has a synergistic 
effect on decreasing cell proliferation of PTC cell lines, proposing that simultaneous targeting of these 
pathways could be effective against the aggressive forms of thyroid cancer. Nonetheless, other signalling 
pathways have been implicated in thyroid tumorigenesis and further investigation of the molecular 
mechanisms behind signalling crosstalk is particularly important to support therapeutic decisions.  
NF-κB is frequently related with thyroid cancer treatment resistance and, for this reason, an effort 
has been made to understand MAPK and NF-κB signalling interplay as well as to develop novel 
therapies targeted toward these pathways.28,35,55,56 Since PI3K/Akt/mTOR is another active player in 
thyroid cancer progression, there is a study demonstrating a synergistic effect between PI3K and NF-
κB suppression in induction of thyroid cancer cell lines’ death, including PTC cell lines.64 However, 
despite this synergistic effect, no direct interplay between these two signalling pathways was shown. 
Recently, our group showed that, in K1 PTC-derived cell line, NF-κB was more easily activated in 
response to RAC1b, in comparison to other thyroid cancer cell lines. Since the distinctive feature of this 
cell line was a PI3KE545K mutation, the hypothesis that PI3K/Akt/mTOR signalling pathway could 
mediate NF-κB activation was raised.4 Thus, the main objective of this work was to analyse if there was 
an interplay between NF-κB and PI3K/Akt/mTOR signalling pathways using the K1 PTC-derived  
cellular model. 
Our first approach was to evaluate the consequences of PI3K/Akt/mTOR pathway inhibition on 
NF-κB activity in K1 cells. Based on literature, we decided to use IκBα mRNA levels as a readout for 
NF-κB transcriptional activity, since this gene is one of the first to be transcribed by NF-κB activation.60 
The results showed an increase of IκBα mRNA relative levels in response to PI3K signalling inhibition, 
which was highest with the PI3K inhibitor Ly294002 (figure 4.1B). This suggests that by blocking PI3K 
signalling, an increase in NF-κB activity occurs. However, when we used immunofluorescence analysis 
of p65 nuclear translocation as a second approach to evaluate NF-κB activation, the opposite is observed. 
As shown by figure 4.2, inhibition of PI3K signalling decreases p65 nuclear staining, suggesting a 
positive effect of PI3K signalling on NF-κB activity.  
Next, we aimed to evaluate the impact of the inhibition of PI3K signalling in the presence of 
exogenous canonical NF-κB stimulation. TNFα is pro-inflammatory cytokine known to activate 
canonical NF-κB. Besides, Bottero et al. (2003) 60 showed that TNFα was able to promote a significant 
increase in IκBα mRNA levels, which was correlated with an increase in NF-κB activity. Accordingly, 
our results showed an increase of IκBα mRNA in response to TNFα, as shown in figure 4.3. However, 
no effect was observed in IκBα mRNA levels upon PI3K/Akt/mTOR inhibition, suggesting that 
PI3K/Akt/mTOR signalling pathway has a low impact on the NF-κB activation status driven by TNFα 
stimulus. Nevertheless, once again, the immunofluorescence data do not seem to support the results 
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obtained by the analysis of IκBα mRNA levels since a decrease on p65 nuclear staining upon treatment 
with PI3K/Akt/mTOR inhibitors is observed also in the presence of TNFα stimulation. 
It remains to elucidate the inconsistency between NF-κB transcriptional readout and p65 nuclear 
translocation. One possible explanation for this inconsistency would be that the optimal time frame to 
analyse the impact on NF-κB activity may differ between the two approaches and may be dependent on 
the nature of the stimulus that drives NF-κB activation. As mentioned above, IκBα is one of the earliest 
transcriptional events triggered by NF-κB activation. In fact, when analysing the short-term effects of 
TNFα stimulation on NF-κB activation status, we observed that the nuclear translocation of p65 is 
followed by an increase in IκBα mRNA levels within a similar time frame. However, upon long 
exposure to PI3K/mTOR inhibitors, the increase observed in IκBα mRNA levels does not appear to be 
associated with increased nuclear localization of p65, but rather its reduction. This raises a possibility 
that the readouts used may require different interpretations when addressing the short- or long-term 
impact on the NF-κB activation status. 
NF-κB activation is a highly dynamic process regulated by negative feedback mechanisms. In fact, 
an increase in NF-κB activity leads to an increase in the transcription of its target genes, which includes 
its own repressor IκBα. Thus, an increase in IκBα gene transcription would eventually lead to an increase 
in IκBα protein levels. IκBα protein not only can retain NF-κB in the cytoplasm, but also has the capacity 
to translocate into the nucleus and bind to NF-κB, repressing its activity and bringing it back to the 
cytoplasm.60,65 Considering that the trigger driving NF-κB activation may have occurred several hours 
before analysis, the decrease in nuclear p65 observed by immunofluorescence could have been preceded 
by an initial increase in p65 nuclear translocation (triggered by NF-κB activation), which tends to 
decrease overtime and was no longer detectable at the timepoints used in this approach. This could also 
suggest that the decrease observed in nuclear p65 may be a consequence of increased IκBα protein 
levels, which resulted from increased long-term NF-κB activity.  
Taking a different perspective, one can also consider the increase in IκBα mRNA levels, observed 
upon PI3K/mTOR inhibition, as a readout of a negative impact of the inhibitors on NF-κB activation 
status. The long-term stimuli induced by the inhibitors could lead to a negative-feedback loop driven by 
a steady-state upregulated IκBα. This, in turn, would result in a decreased level of active NF-κB, which 
may be consistent with the decreased nuclear staining of p65 upon treatment with PI3K/mTOR 
inhibitors. Unfortunately, we did not have the opportunity to add more replicates to the 
immunofluorescence data, so significance of nuclear p65 translocation results are debatable. Even 
though, altogether, our data support an impact of PI3K signalling on NF-κB activity. However, whether 
the final outcome of this impact is the up- or down-regulation of NF-κB activation status, needs further 
investigation. Future studies addressing NF-κB activity using reporter genes, evaluation of IκBα levels 
and phosphorylation status and analysis of other NF-κB transcriptional targets would be relevant to 
clarify the results obtained. Also, besides the canonical NF-κB pathway, other signalling pathways may 
be involved in the transcriptional modulation of IκBα gene and the effects induced by PI3K signalling 
inhibition on IκBα mRNA levels could result from the action of pathways other than NF-κB signalling. 
To test this, we used the allosteric inhibitor of the IKK complex BMS-34541, which preferentially 
inhibits IKKβ catalytic subunit over IKKα.61 Once  IKKβ activity is more related with canonical NF-κB 
(while non-canonical pathway is mostly linked to IKKα  subunit activity) 65,  BMS-345541 can be 
considered mainly an inhibitor of the canonical NF-κB pathway.  The presence of BMS-345541 
hampered the increase on IκBα mRNA levels observed upon PI3K inhibition, supporting that this 
increase is, mostly occurring through canonical activation of NF-κB. 
Gathered evidence support the relevance of the interplay between PI3K and MAPK pathways in 
thyroid tumorigenesis.20,54,66 Also an interplay between NF-κB and MAPK pathway in thyroid cancer 
cellular systems was described.66 Accordingly, Palona et al. (2006) 56 described that BRAFV600E protein 
activates NF-κB, independently of MEK-ERK signalling 56 and Namba et al. (2007) 35 supplemented 
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this information adding evidences that BRAFV600E activates NF-κB through IκBα phosphorylation.  
Thus, since K1 cell line is characterized for having both BRAFV600E and PI3KE542K point mutations, which 
consequently promote constitutive activation of MAPK and PI3K/Akt/mTOR pathways, respectively 
4,24, it was important to elucidate if the effects observed with PI3K signalling inhibition on NF-κB 
transcriptional activity were being affected by other signalling pathways. Therefore, we decided to 
compare the effects of PI3K/mTOR inhibitors observed in K1 cells with two other PTC systems with 
different genetic backgrounds: the BCPAP cell line, which unlike K1 only harbours the BRAFV600E point 
mutation and TPC1 that harbours a RET/PTC rearrangement, which can also signal through both MAPK 
and PI3K/Akt/mTOR pathways.4,24 Notably, the strongest impact of PI3K signalling inhibition on NF-
κB translational readout was observed in K1 cells, supporting that PI3K signalling influences NF-κB 
only if the pathway is activated by oncogenic mutation in PI3KCA gene. 
Evidences supporting a crosstalk between NF-κB and PI3K/Akt/mTOR signalling pathways were 
seem in several cancer systems, including glioblastoma67, head and neck squamous cell carcinoma68 , 
primary effusion lymphoma 69,  prostate cancer 70,71 as well as in some other systems such as breast and 
lung cancer, indicating that NF-κB is a downstream effector of Akt and, in some cases, mTORC1, which 
is positively regulated after by PI3K/Akt pathway activation.72 Although our data support that 
PI3K/Akt/mTOR impacts on NF-κB activity, it remains to be elucidated whether this impact leads to 
the overall increase or decrease of NF-κB activity. Actually, Gao et al. (2016) 71 propose that within 
PI3K/Akt/mTOR pathway, TSC2 could also modulate NF-κB activity either through its inhibition or 
stimulation, depending on PTEN status. Thus, in future experiments, evaluation of TSC2 and PTEN 
status could complement and clarify the results obtained with this work. Moreover, since many authors 
refer a positive effect of PI3K/Akt/mTOR on NF-κB activity through IKK axis 68,71,73, evaluation of this 
kinase activity in our cellular system could also be performed. 
5.1. Main conclusions 
The aim of this thesis was to evaluate if there was a potential interplay between NF-κB canonical 
signalling and PI3K/Akt/mTOR pathway in PTC cellular systems.  
Our approach consisted in the analysis of NF-κB activity in the presence of PI3K/Akt/mTOR 
pathway inhibitors via three different conditions: i) without an exogenous impact on NF-κB activation 
status ii) in the presence of NF-κB exogenous stimulation iii) in the presence of a NF-κB inhibitor.  
We observed that, in the K1 cellular model with constitutive PI3K signalling activity, the inhibition 
of PI3K signalling led to the increase of the NF-κB transcriptional target IκBα, consistent with an 
increase in NF-κB activity (except when in the presence of an NF-κB exogenous stimulator). The 
increase observed in NF-κB transcriptional readout, however, was not associated with an increase in 
nuclear translocation of p65 but rather with its decrease. This apparent inconsistency between NF-κB 
transcriptional activity and nuclear translocation made us raise the hypothesis that the observed 
transcriptional effect on IκBα may have been driven by other signalling pathways. However, the 
inhibition of the canonical pathway of NF-κB activation reverted the impact of PI3K inhibition, 
suggesting that the effect on NF-κB transcriptional readout is mostly dependent on NF-κB canonical 
activation.  
Regulation of NF-κB signalling pathway involves production of its own repressor as a homeostatic 
control mechanism for NF-κB activity. Considering this negative-feedback control, we can always 
speculate that an increase in IκBα mRNA, will eventually give rise to an increase in IκBα protein levels, 
which in turn will inhibit NF-κB activity. Thus, when using IκBα as a transcriptional readout for NF-κB 
activation it is important to take into account that short-term and long-term exposures could result in 
different outcomes and interpretations. This could explain why in our work the short-term TNFα 
exposure is perfectly correlated in both transcriptional and nuclear translocation analyses, while with 
long-term exposures for PI3K/mTOR inhibitors inconsistencies are observed. In this case, it seems 
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plausible to think in IκBα mRNA levels increase as a consequence of an increase on NF-κB activation 
and since this effect was a result of a long-term exposure, it is probable that at the time of observation 
part of IκBα mRNA was already transcribed into IκBα protein, resulting in the decrease of NF-κB 
nuclear translocation. 
Understanding the molecular mechanisms behind signalling crosstalk in papillary thyroid cancer, 
could provide essential knowledge to the development and management of targeted therapies, 
particularly in patients with advanced forms of disease. Our data unravels a potential interplay between 
PI3K/Akt/mTOR pathway and NF-κB signalling in PTC, which may be modulated by tumour genetic 
background. Although we could not provide the exact mechanism by which this crosstalk occurs, 
patients should be evaluated and treated according to the functional status of molecular players behind 
key signalling pathways, in order to obtain the most adequate therapy and prevent treatment resistance. 
5.2. Future Perspectives 
In order to clarify the results obtained throughout this work, in the future it would be relevant to: 
- Evaluate IκBα protein status. 
- Analyse NF-κB activity using reporter-plasmid systems designed for monitoring NF-κB 
transcriptional activity. 
- Test other NF-κB translational target genes, such as Bcl-2, Cyclin D1, XIAP and cIAP by RT-
qPCR.  
- Evaluate the effects of BMS-345541 inhibitor on IKKα/β phosphorylation, as well as on NF-
κB nuclear translocation. 
- Evaluate PTEN, Akt, TSC2 and IKK activation status upon modulation of PI3K and NF-κB 
signalling. 
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Appendix - Solutions prepared for the experimental work: 
 
 
 
PCR buffer10x 
100 mM Tris-HCl 
500 mM KCl  
15 mM MgCl2 
0.1% (w/v) gelatin 
 
Western Blot Solutions 
 
Sample Buffer 2x 
 
For 250 µM 
100 µL SB 2x 
150 µL water 
0.5 µl benzonase 
2.5 µl magnesium chloride  
 
 
Blot buffer 25x 
 
For 1 L: 
1.25 g SDS 
145 g tris 
72.5 g glycine 
H2O till 1 L 
 
 
SDS Page 10x 
 
For 2.5L: 
2.5 g SDS 
76g tris 
360.3 glycine 
H2O till 2.5L 
 
 
Comassie stain 
 
For 500 mL: 
1.25 g brilliant blue 6 (sigma) 
225 mL methanol 
50 mL acetic acid 
H2O till 500 mL 
 
 
Comassie destain 
 
For 1 L: 
450 mL methanol 
100 mL acetic acid  
H2O till 1 L 
 
 
 
TBST 1x 
 
For 1.5L: 
100 mL TBS 10x 
900 mL H2O 
500 mL triton 
 
 
TBST milk 
 
For 50 mL: 
10 mL powder milk 
40 mL TBST  
 
Running gel 10% 
 
1.9 mL H2O 
1.3 mL lower buffer 
1.7 mL acrylamide 
50 µL SDS 10% 
50 µL APS 10% 
2 µL TEMED 
 
Stacking gel 4% 
 
1.4 mL H2O 
0.25 mL upper buffer 
0.33 mL acrylamide 
20 µL SDS 10% 
20 µL APS 10% 
2 µL TEMED 
 
ECL solution 1 
 
100 mM Tris-HCL 
pH 8.8 
3.75 mM Luminol 
450 µM cumaric ácid 
 
 
 
ECL solution 2 
 
100 mM Tris pH 8.8 
0.1 % (v/V) H2O2 
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Supplementary table II 
